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ABSTRACT 
        A large number of simple or complex translocation involving the CML and AML chromosomal 
abnormalities has been described. This study was aimed to investigate the complex chromosome aberrations 
in the series of myeloid malignancies including CML and AML. The present report deals analyzed 187 
consecutive with CML and AML patients, using Methotrexate  cell synchronization and  un-stimulated 
cultures of   cells to determine the incidence of chromosomal aberrations and association of complex variant 
chromosome anomalies according to  French American British morphological subtypes. The results revealed 
an abnormal karyotype with a novel complex translocation involving chromosomes 1,2,4,9,11,22.  Complex 
variant translocations   were found in two cases of AML and two cases of CML. The present reports 
provides sufficient grounds for assuming that a chromosomes involving of complex abnormalities  plays an 
important  role in the development of malignancy.   
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INTRODUCTION 
        Chromosomal abnormalities in neoplasia  
appear to be nonrandom and tend to cluster to 
certain chromosomes. All human chromosomes 
except the Y chromosome have been involved in 
complex chromosome translocation [1]. Acute 
Myeloid Leukemia (AML) is a malignant 
neoplasm of hematopoietic stem cells 
characterized by an abnormal proliferation of 
myeloid precursors, a reduced rate of apoptosis, 
and an arrest in cellular differentiation[2]. Variant 
t(8;21) translocations have been reported in 6–
10% of cases with the RUNX1/CBFA2T1 fusion 
gene [3]. The majority of these patients shows 
three way complex translocations involving 
another chromosome in addition to 8q22 and 
21q22 [4], whereas few reports have shown the 
occurrence of four-way rearrangements [5].  
Chronic Myeloid Leukemia (CML) is a 
myeloproliferative disorder characterized by the 
presence of the Philadelphia chromosome (Ph) 
and the formation of the BCR-ABL1 fusion. More 
than 85% of cases of CML are characterized by 
the presence of Ph chromosome in their bone 
marrow, the remaining of the cases a translocation 
between chromosome 22 and other than 9, or 
complex three or four way translocation are 
identified [6]. Variants of the Philadelphia 
translocation and complex translocations 
involving BCR have been reported in 
myeloproliferative disorders [6]. A rare 
translocation, t(9;22)(p24;q11.2), resulting in a 
novel BCR-JAK2 fusion has been reported in a 
handful of cases of chronic  and acute 
myelogenous leukemia [7]. 
 
MATERIALS AND METHODS 
     The total of 187 of de novo AML and CML 
patients were selected on the basis of complexity 
of the chromosome abnormalities. Complexity 
was defined as the presence of three or more 
different chromosome   abnormalities in the 
malignant clone and/or variant i.e., changes from 
cell to cell despite the presence of a clonal origin. 
 Cytogenetic analysis 
 




       As part of thesis research and project  study, 
we used these data to investigate the chromosome 
1,2,4,9,11,22    abnormalities in complex 
chromosome aberrations  in myeloid 
malignancies.  During the last twelve years, 
chromosome banding studies were performed on 
187 unselected consecutive either  adults sex  
patients with de novo CML and AML  admitted to 
the  major referral hospitals affiliated of Shahid  
Beheshti University of  Medical Sciences, Tehran, 
Iran.  
Conventional cytogenetic studies of a 24- to 48-h 
culture were carried out on bone marrow cells by 
standard methods and evaluated by giemsa–
trypsin–giemsa banding according to the ISCN 
[8]. A minimum of 20 metaphases were analyzed. 
Approximately 0.5 ml of  bone marrow / 
peripheral blood was obtained from each 
participant. The blood sampling and cell culture 
procedures were essentially the same for all the 
participants. Briefly, heparanized blood was 
immediately mixed with 4 ml RPMI – 1640 
(Gibco BRL, USA)cell cultured medium 
supplement with 15-20% heat inactivated fetal 
bovine serum (Gibco BRL, USA), 100mg/ml 
Phytohemagglutinin (PHA) in a Vacutainer tube 
(Becton  Dickinson Co, Ltd USA). This tube 
cultured for 70 hours at 37Ċ under the aeration of 
5% Co2 in the incubator. After an incubation 
period, the cultured cell harvested by 75 ml 
colcemide 10µg/ml (Gibco BRL USA) and 
incubated at 37Ċ for 30 minutes. The contents of 
the tube were then centrifuged for 10 min at 1000 
rpm and resuspended in 10 ml of 75 mM Kcl 
0.56% (Sigma, Co) prewarmed to 37Ċ for 20 min. 
At this stage 1ml of 20Ċ Carnoys Fixative 3:1 
methanol: acetic acid (Fisher Scientific) was 
added in to the tube to stop further cell swelling. 
This fixation repeated four times. Then cells 
dropped on to clean slides, and cultured for 3 days 
at 60Ċ on the slide warmer. Slides then banded 
for 10 second with 0.2 X trypsin (Difco, Co USA) 
and stained for 3 min Giemsa (Harleco, Co) [9]. 
Slides were examined with an Olympus model 
BH-2 light microscope. Eighty well spread G-
banded metaphases were analyzed. 
 
RESULTS 
            Cytogenetic analysis of bone marrow cells 
revealed an abnormal karyotype with a novel 
complex translocation involving chromosomes 
1,2,4,9,11,22. Complex variant translocations   
were found in two cases of AML and two cases of 
CML. This study demonstrates unique cases of 
two complex variant translocations designated as, 
the three-way translocation was confirmed with 
spectral karyotyping t(2;4;21) and other with 
t(2;4) and monosomy 21 seen independently in 
the same patient M2-AML. Another patient with a 
rare or not yet described chromosomal aberration, 
exhibited t(9;22), der(22) (9;22), ring 
chromosome 15 and two marker chromosomes, 
seen in 5 cells in M2-AML. 
 
 
Figure. 1 Karyotype of bone marrow cell showing 
46,XX,t(2;5;9;22).  
 
In CML patient, in whom complex translocation 
was noticed, showed 46,XY, t(1,9,11,22) in 5 
cells. In the second patient, a 24 years old female, 
cytogenetic study indicates clonal abnormality 
involving complex  Ph translocation viz., 46,XX, 
t(2;5;9;22) in 8 cells (Figure.1). In all cases had 
complex chromosomal abnormalities without any 
history of previous malignant diseases or 
 




occupational or therapeutic exposure.  The 
percentage of all abnormal cytogenetic cells was 
recorded to be between 25 to 100% . The 
distribution of total chromosomal changes 
revealed as Figure2 [10-11]. 
 
 
Figure 2. Distribution of chromosomal damages in myeloid leukemia 
 
DISCUSSION 
     A large number of simple or complex 
translocation involving the CML and AML 
chromosomal abnormalities have been described 
in the current literature [12-18]. The present 
report describes cases of CML and AML-M2 with 
a unusual translocation involving chromosomes 
1,2,4,9,11,22  with the various  break points.  
Complex translocations of  t(8;21), involving 
chromosome 1, 5, 6, 11, 12, 15, 17, or 19 have 
been reported elsewhere[19-20],  in patients with 
AML (M2) with similar clinical features as those 
of t(8;21), including good response to therapy. 
These cases with complex translocations, 
including the importance of AML1-MTG8(ETO) 
transcript in the leukemogenesis of M2/t(8;21) as 
a result of AML-M2 previously demonstrated 
[21]. In the majority of t(8;21) AML cases with 
complex translocations a third chromosome is 
generally involved in the rearrangement [19-21]. 
Few cases bearing a four-way variant t(8;21) have 
been described and a detailed molecular 
cytogenetic characterization of the breakpoints 
has never been attempted[15]. Using appropriate 
BAC/PAC clones we have defined the 
chromosomal breakpoints of a complex 
t(8;11;16;21) in an AML case, accompanied by 
large chromosomal deletions which did not affect 
the chromosome 8 sequences. Indeed, the 
5_RUNX1/3_CBFA2T1 fusion gene was 
observed, as expected, on der(8). The precise 
breakpoints characterization the presence of 
submicroscopic deletions of chromosome 11 and 
16 sequences reported,  by Albano and co-
workers, in the year  2005[15]. The general results 
of this study are in good agreement with 
previously reported findings in the series of 
complex chromosomal abnormalities,   with CML 
and AML patients. 
 
CONCLUSSION 
   In conclusion, these findings confirmed 
previous data showing that in hematologic 
malignancies several reciprocal complex 
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